ProSensa Holding N.V. Initiates First Patient Dosing in Phase I/II trial of PRO053
Published: Sep 06, 2013
s Leiden, The Netherlands, Sept. 6, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the dosing of the first patient in its Phase I/II clinical trial of PRO053, an exon-skipping compound for the treatment of Duchenne muscular dystrophy (DMD).
Help employers find you! Check out all the jobs and post your resume.